KalVista Pharmaceuticals (KALV) Net Cash Flow Growth (3y) (2019 - 2025)
KalVista Pharmaceuticals (KALV) Net Cash Flow Growth (3y) (2019 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
814,307.08 Bn |
814,307.05 Bn |
- |
- |
| 2 |
Belite Bio |
55,320.00 Bn |
55,320.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,149.72 Bn |
17,149.72 Bn |
- |
- |
| 4 |
Legend Biotech |
3,590.00 Bn |
3,589.71 Bn |
242.10 Mn |
89.97% |
| 5 |
Akari Therapeutics |
1,650.72 Bn |
1,650.72 Bn |
- |
-13.44% |
| 6 |
Evaxion A |
1,522.09 Bn |
1,522.07 Bn |
- |
- |
| 7 |
Psyence Biomedical |
229.39 Bn |
229.38 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.09 Bn |
105.85 Bn |
2.59 Bn |
33.37% |
| 9 |
Abivax |
90.15 Bn |
90.15 Bn |
- |
- |
| 10 |
KalVista Pharmaceuticals |
1.44 Bn |
1.25 Bn |
56.41 Mn |
-49.52% |
| Date | Value |
|---|
| Jul 31, 2025 |
-49.52% |
| Apr 30, 2025 |
-40.03% |
| Oct 31, 2024 |
91.94% |
| Jul 31, 2024 |
70.44% |
| Apr 30, 2024 |
-35.47% |
| Jan 31, 2024 |
-223.98% |
| Oct 31, 2023 |
98.53% |
| Jul 31, 2023 |
-76.60% |
| Apr 30, 2023 |
-123.41% |
| Jan 31, 2023 |
151.81% |
| Oct 31, 2022 |
67.08% |
| Jul 31, 2022 |
94.14% |
| Apr 30, 2022 |
16.48% |
| Jan 31, 2022 |
81.85% |
| Oct 31, 2021 |
-26.51% |
| Jul 31, 2021 |
-7.09% |
| Apr 30, 2021 |
88.03% |
| Jan 31, 2021 |
-66.40% |
| Oct 31, 2020 |
40.74% |
| Jul 31, 2020 |
34.49% |
